Hair analysis differentiates chronic from acute carbamazepine intoxication

Pediatric Neurology

Volumn 31, Issue 1, 2004, Pages 73-75

  Mantzouranis, Evangelia C ^a,c   Bertsias, George K ^b,c   Pallis, Eleftherios G ^b,c   Tsatsakis, Aristidis M ^b,c  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENYTOIN;

ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; COMA; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG INTOXICATION; ELECTROENCEPHALOGRAM; EMERGENCY WARD; EPILEPSY; FEMALE; HAIR ANALYSIS; HOSPITALIZATION; HUMAN; LABORATORY TEST; MEDICAL ASSESSMENT; NEUROLOGIC EXAMINATION; NEUROTOXICITY; OXYGEN SATURATION; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ACUTE DISEASE; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; EPILEPSY; FEMALE; HAIR; HUMANS;

EID: 3142649053     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2003.12.017     Document Type: Article

References (14)

1. Bertilsson L., Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. Clin Pharmacokinet. 11:1986;177-198
2. Warner A., Priviteza M., Bates D. Standards of laboratory practice Antiepileptic drug monitoring. Clin Chem. 44:1998;1085-1095
3. Tsatsakis A.M., Tzatzarakis M. Sectional hair testing Judicial and clinical applications. Pure Appl Chem. 72:2000;1057-1066
4. Psillakis T., Tsatsakis A.M., Christodoulou P., Michalodimitrakis M., Paritsis N., Helidonis E. Carbamazepine levels in head hair of patients under long-term treatment A method to evaluate the history of drug use. J Clin Pharm. 39:1999;55-67
5. Montgomery V.L., Richman B.J., Goldsmith L.J., Rodgers G.C. Jr. Severity and carbamazepine level at time of initial poison center contact correlate with outcome in carbamazepine poisoning. J Toxicol Clin Toxicol. 33:1995;311-323
6. Delgado Iribarnegaray M.F., Santo Bueldga D., Garcia Sanchez M.J., Otero M.J., Falcao A.C., Dominquez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 19:1997;132-139
7. Schmidt S., Schmitz-Buhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 242:1995;169-173
8. Weaver D.F., Camfield P., Fraser A. Massive carbamazepine overdose Clinical and pharmacologic observations in five episodes. Neurology. 38:1988;755-759
9. Evans W.E., Relling M.V. Pharmacogenomics Translating functional genomics into rational therapeutics. Science. 286:1999;487-491
10. Pearce R.E., Vakkalagadda G.R., Leeder J.S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 30:2002;1170-1179
11. Steimer W., Potter J.M. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 315:2002;137-155
12. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:2002;1271-1294
13. Williams J., Patsalos P.N., Mei Z., Schapel G., Wilson J.F., Richens A. Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit. 23:2001;15-20
14. Eichelbaum M., Kroemer H.K., Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett. 64-65:1992;115-122